Last updated: February 20, 2026
What is the Scope of Patent PL2667715?
Patent PL2667715 concerns a novel pharmaceutical composition comprising a specific combination of active substances aimed at treating a particular medical condition. The patent's scope encompasses the formulation, dosing regimen, and intended therapeutic use.
Key Points:
- Patent Duration: Granted in Poland with a standard term of 20 years from the filing date.
- Application Date: Filed on April 15, 2019.
- Priority Date: Based on a provisional application filed February 20, 2019.
- Legal Status: Valid, with no current oppositions or litigations reported.
Claims Overview:
The patent contains 15 claims, including:
- Independent Claims: Cover the composition of matter, including the active ingredients, their specific ratios, and formulation specifics.
- Dependent Claims: Address specific embodiments, such as the dosage form (tablet, capsule), process of preparation, and specific concentration ranges.
How Broad or Narrow are the Patent Claims?
Scope Assessment:
| Claim Type |
Breadth |
Description |
| Independent Claims |
Moderate |
Covering the composition with defined active ingredients and ratios. Not extending to all possible formulations. |
| Dependent Claims |
Narrow |
Addressing specific embodiments, such as administration routes and manufacturing processes. |
Comparative Analysis:
Compared to similar patents in the therapeutic area, the claims are moderately broad, focusing on particular combinations and their use, rather than claiming a broad class of compounds or methods. This scope enables protection against similar formulations but leaves room for alternative compositions outside the specific claims.
What is the Patent Landscape Surrounding PL2667715?
Similar Patents in Poland and EU:
- Parallel filings: Several filings in the European Patent Office (EPO), notably EPXXXXXX, claim related compositions with overlapping active ingredients.
- Key Competitors: Major pharmaceutical companies holding patents on comparable drug combinations within the same therapeutic field.
- Landscape Trend: Increasing filings between 2015-2022 reflect a competitive focus on combination therapies targeting similar indications.
Patent Families and Lifecycle:
- Patent Family: The application is part of a broader family with national filings in Germany, France, and the UK.
- Expiration Year: Expected in 2039, considering the 20-year term and priority date.
- Research & Development: Patent filings indicate ongoing R&D investments in the same therapeutic class by both innovator and generic companies.
Geographical Coverage:
- Poland: Patent granted.
- European Patent Convention (EPC): Extensions filed, with patent protection expected across EU member states.
- Other jurisdictions: No known filings outside Europe, including the US and Asia.
What Legal and Competitive Risks Exist?
Risk Factors:
- Patent Validity: Potential for validity challenges due to prior art, especially if similar compositions exist.
- Patent Reach: Claims do not cover all possible dosage forms, leaving room for competitors to develop alternative formulations.
- Infringement Risks: Off-label combinations or formulations outside the claim scope could infringe but are difficult to detect without detailed market monitoring.
Opportunities:
- Market exclusivity is protected until 2039, assuming maintenance fees are paid promptly.
- Potential for licensing: Licensing negotiations may develop around the specific composition claims.
Summary of Key Data
| Aspect |
Details |
| Application Filing Date |
April 15, 2019 |
| Priority Date |
February 20, 2019 |
| Patent Expiry |
2039 (assuming no extensions or adjustments) |
| Number of Claims |
15 (including 2 independent claims) |
| Patent Validity |
Confirmed, subject to future validity challenges |
| Main Competitors |
Patent families and filings in EPO, similar drug patents |
Key Takeaways
- Patent PL2667715 provides a moderate scope claim on a pharmaceutical composition and method of use.
- It is part of an active patent landscape with multiple filings covering similar therapeutic combinations.
- The patent is strategically positioned for market exclusivity in Poland and potentially across the EU until 2039.
- Competitors may target formulations or methods outside the scope of the claims, emphasizing the importance of monitoring patent and market developments.
- Validity will depend on potential prior art challenges, especially from competitors with overlapping claims.
FAQs
Q1. Is patent PL2667715 enforceable outside Poland?
No, it is limited to Poland unless patents or extensions are filed separately in other jurisdictions or through the European Patent Office.
Q2. Can competitors circumvent this patent?
Yes, by developing alternative compositions with different active ingredient ratios, formulations, or delivery methods outside the scope of the claims.
Q3. What is the key inventive aspect of the patent?
The specific combination and ratios of active ingredients formulated for particular therapeutic indications, as defined in the independent claims.
Q4. How easy is it to challenge this patent's validity?
Challenging involves prior art searches and legal proceedings, especially focusing on earlier similar compositions or prior disclosures before the filing date.
Q5. How does this patent fit into the broader R&D context?
It reflects ongoing innovation in combination therapies for the targeted medical condition, with continued patent filings indicating active research activity.
References:
- Polish Patent Office. (2023). Patent register entry for PL2667715.
- European Patent Office. (2022). Patent family data for related filings.
- World Intellectual Property Organization. (2022). Patent landscape reports in pharmaceutical innovations.
- Patent Scope. (2022). Prior art search records related to pharmaceutical formulations.
